SavedAdd your journal

Journals / Genel Tıp Dergisi / 2021 / Cilt: 31 - Sayı: 2

Investigating of Effects of Metformin on Melanoma Skin Cancer

Metforminin Melanom Cilt Kanseri Hücreleri Üzerindeki Etkisinin Araştırılması

Harun ALP
Hidayet TUTUN
Levent ALTINTAŞ
Halil Mahir KAPLAN
Ergin ŞİNGİRİK
İbrahim KAHRAMAN
Pages
111–115
Publication Date
2021-06-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: In conclusion, our study showed that metformin has apoptotic effect on melanoma skin cancer.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Apoptotic pathways are important for resistance to chemotherapeutics drugs and cancer development.
📊
Key Findings & Data:Metformin is a safe, inexpensive and effective drug used to treat type 2 diabetes.
💡
Conclusion & Impact:Conclusion: In conclusion, our study showed that metformin has apoptotic effect on melanoma skin cancer.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Metformin · Melanom cilt kanseri · kaspaz-3

Abstract

Aim: Apoptotic pathways are important for resistance to chemotherapeutics drugs and cancer development. Metformin is a safe, inexpensive and effective drug used to treat type 2 diabetes. Furthermore, although there is evidence of anticancer effects, the mechanisms by which metformin exerts this effect are unclear. If metformin is thought to be safe, cheap and effective drugs, the potentially beneficial effects of these drugs are of great importance. Therefore, it was aimed to investigate Bcl-2, kaspaz-3, bax, wee-1, AIF, grp78 and gadd153 levels in metformin treated skin cancer cells. Materials and Methods: For this propose we prepared culture of skin cancer cells then these cells were treated with metformin and it was analyzed kaspase-3, bcl-2, wee 1, gadd153, grp78 and AIF protein levels by ELISA on these cells. Result: Treatment of metformin increased of proapoptotic proteins (kaspase-3, bcl-2, wee 1, gadd153, grp78 and AIF) and decreased antiapoptotic protein (bcl-2). Conclusion: In conclusion, our study showed that metformin has apoptotic effect on melanoma skin cancer.

Özet

Amaç: Kanserlerde kemoterapötiklere gösterilen dirençte ve kanser gelişiminde apoptozisin önemli rolü vardır. Metformin tip 2 diyabet tedavisinde kullanılan güvenli, ucuz ve etkili bir ilaçtır. Ayrıca, antikanser etkilerinin olduğuna dair kanıtlar olmasına rağmen metforminin bu etkiyi hangi mekanizmalar ile gerçekleştirdiği açık değildir. Bu nedenle, çalışmamızda cilt kanseri hücrelerine metformin uygulamasının Bcl-2, kaspaz-3, bax, wee-1, AIF, grp78 ve gadd153 düzeyleri üzerine etkileri araştırıldı. Gereç ve Yöntem: İlgili protein düzeylerinin belirlenmesinde ELISA testleri kullanıldı. Bulgular: Çalışmamızda metforminin cilt kanseri hücrelerinde apoptozis proteinlerini (kaspaz-3, wee 1, gadd153, grp78 ve AIF) arttırdığı ve antiapoptotik markırı (bcl-2) azalttığı belirlendi. Sonuç: Sonuç olarak çalışmamız; metforminin melanom cilt kanseri üzerine apoptotik etkisinin olduğunu göstermiştir.

🔖

Cite This Article

ALP, H., TUTUN, H., ALTINTAŞ, L., KAPLAN, H. M., ŞİNGİRİK, E., KAHRAMAN, İ. (2021). Investigating of Effects of Metformin on Melanoma Skin Cancer. Genel Tıp Dergisi, Cilt: 31 - Sayı: 2, 111–115. https://ajindex.com/articles/726193

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Bailey CJ, Day C. Metformin: its botanical background. Practical Diabetes Int 2004; 21: 115. Del Barco S, Vazquez-Martin A, Cufi S, Oliveras-Ferraros C, Bosch-Barrera J, Joven J. et al. Metformin: multi-faceted protection against cancer. Oncotarget 2011; 2: 896-917.
  2. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci 2012; 122 (6): 253-270.
  3. Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle 2010; 9 (6): 1057-1064.
  4. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330: 1304-1305.
  5. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer 2011; 11:20. doi: 10.1186/1471-2407-11-20.
  6. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009; 32: 1620-1625.
  7. Pulito C, Donzelli S, Muti P, Puzzo L, Strano S, Blandino G. microRNAs and cancer metabolism reprogramming: the paradigm of metformin. Ann Transl Med 2014; 2 (6): 58. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 1816):926-945.
  8. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin–dependent translation initiation in breast cancer cells. Cancer Research 2007; 67 (22): 10804-10812.
  9. Han G, Gong H, Wang Y, Guo S, Liu K. AMPK/mTOR-mediated inhibition of survivin partly contributes to metformin-induced apoptosis in human gastric cancer cell. Cancer Biol Ther 2015; 16 (1): 77-87.
  10. Honjo S, Ajani JA, Scott AW, Chen Q, Skinner HD, Stroehlein J. et al. Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer. Int J Oncol 2014; 45 (2): 567-574.
  11. Kalender A, Selvaraj A, Kim SY, Gulati P, Brûlé S, Viollet B. et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab 2010; 11: 390-401.
  12. Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AK, Gans RO. et al. Metformin: taking away the candy for cancer? Eur J Cancer 2010; 46 (13): 2369-2380. Kahn